Summary Ten previously untreated postmenopausal women with metastatic breast cancer, none of whom had received prior systemic therapy, were treated with the luteinising hormone releasing hormone (LHRH) analogue D-Ser(But)6, Azgly'0-LHRH (ICI 118630). Two obtained an objective partial remission, one in bone metastases and one in lung metastases. One patient proved unassessable. Amongst the seven failures, incomplete pituitary gonadotrophin suppression over the relatively short treatment period with the daily injections was noted. The seven patients failing ICI 118630 received tamoxifen and two with high tumour oestrogen receptor values responded.
A number of luteinising hormone releasing hormone (LHRH) agonists are currently undergoing clinical trials in the treatment of advanced breast cancer in premenopausal women (Klijn & Jong, 1982; Nicholson et al., 1984; Tolis et al., 1981) and prostate cancer in men (Tolis et al., 1984; Borgman et al., 1982; Waxman et al., 1983; Allen et al., 1983; Ahmed et al., 1983; Walker et al., 1983) .
The preliminary endocrinological data appear encouraging and show that LHRH agonists act to down-regulate pituitary LHRH receptors and hence cause a desensitisation of the pituitary gland to the releasing properties of the drugs. This results in a fall in circulating gonadotrophins: luteinising hormone (LH) and follicle stimulating hormone (FSH) and consequently a reduction of gonadal steroidogenesis (Klijn & Jong, 1982; Nicholson et al., 1984; Tolis et al., 1981 Tolis et al., , 1982 Borgman et al., 1982; Waxman et al., 1983; Allen et al., 1983; Ahmed et al., 1983; Walker et al; , 1.983) . The ability of these compounds to reduce; gonadal function is often associated with tumour remissions (Klijn & Jong 1982; Tolis et al., 1984; Borgman et al., 1982; Waxman et al., 1983; Allen et al., 1983; Ahmed et al., 1983) . Interestingly, one LHRH agonist leuprolide (D-Leu-6-des Glyt0-LHRH ethylamide) has also been reported to induce short lived tumour remissions in 12/31 postmenopausal women with advanced breast cancer (Harvey et al., 1981) . The present study reports the clinical and endocrinological effects of a potent LHRH agonist ICI 118630 (LHRH) analogue (D-Ser(Bu')6 Azgly10-LHRH) in asymptomatic, postmenopausal women with assessable breast cancer none of whom had received previous systemic therapy. subcutaneous injections of the drug (250 ,ug in citrate buffer; 0.5 ml). The four later patients received monthly subcutaneous injections of a depot formulation containing 3.6mg of the drug. In the depot formulation, ICI 118630 was incorporated in a lactide-glycolide co-polymer in the form of a small cylindrical rod. This was injected under local anaesthesia, through a 16 gauge needle into the subcutaneous tissue of the anterior abdominal wall.
Materials and methods

Study design
Chemical endocrine data Serum oestrone and DHA-sulphate were measured using conventional radioimmunoassay techniques. These assays featured tritiated radioligands and liquid-phase antisera and used dextran-coated charcoal to separate antibody-bound and free steroid. Oestrone was extracted from plasma using diethyl ether prior to assay, whilst DHA-S was assayed directly in diluted plasma (Cameron et al., 1975; Smith et al., 1975) .
Serum cortisol was measured using a direct radioimmunoassay procedure using an 12511 radioligand and a solid-phase antiserum (RiadFahmy et al., 1979) . Testosterone and adrostenedione both required pre-assay extraction with diethyl ether and were measured in radioimmunoassays using 125I-radioligands and antisera coupled to magnetisable, solid-phase supports (Dyas et al., 1979; Read et al., 1962) .
Oestradiol and progesterone were measured using commercially available kits (Steranti Research Ltd; Diagnostic Products Ltd). Luteinising hormone, follicle stimulating hormone and prolactin were measured using a double antibody radioimmunoassay procedure (Groom, 1977 (Figure 1 ). Local ethical committee approval for drug usage ceased at three months and after day 89, the patient was placed on tamoxifen (20mg orally twice daily). She remained well until day 496 when a further MDP bone scan demonstrated recurrence in the same bony sites. At this time, plain X-rays and CT scanning of the 'hot' lumbar vertebrae were diagnosed as typical of metastatic involvement by a diagnostic radiologist quite independent of this study.
Gonadotrophin data: At presentation serum LH/FSH (IU -1) concentrations were raised (40/56) and showed stimulation during early days (D) of treatment (D1, + 2 h: >501>80) but by 12 days less stimulation was noted (pre-injection: 5/9, +2 h: 8/11) and suppression was marked thereafter (D36, pre-injection: 8/13, + 2 h:<0.7/9).
Patient 2 Presented at age 49 as a premenopausal lady with apparently early and localised breast cancer. She was treated by mastectomy for infiltrating duct carcinoma. The ER/PR status is unknown. Five years later, now three years postmenopausal, the chest X-ray and later CT lung scan ( Figure 2 ) showed multiple pulmonary masses. She was asymptomatic. MDP bone scanning and liver ultrasound scans were clear, as was the clinical examination. Therapy was commenced with ICI 118630 by monthly depot injection. The patient's pulmonary metastases achieved a partial response (Figure 3 ), which persists into the thirteenth month (at the time of writing) and the therapy continues.
Gonadotrophin data: At presentation serum LH/FSH values were raised (24/30). There was no evidence of early gonadotrophin stimulation with this depot injection (D4, 21/18) but suppression was obvious at day 7 (16/14) and was profound thereafter (D14, 1/4; D21, <0.7/1; D28, <0.7/1; D42, <0.7/2; D56, <0.7/4).
Non responders
Patient 3 Presented at age 43 years with bilateral breast cancer for which she was treated by bilateral mastectomy and, although there was no apparent metastatic disease, she underwent bilateral oophorectomy. There are no ER/PR data. Sixteen years later, the patient developed a bone relapse and extradural compression. She was treated by local radiotherapy to the spine and ICI 118630 daily s.c. injections. After four weeks of treatment the MDP bone scan showed no response. Tamoxifen therapy was substituted but serial MDP bone scanning demonstrated progression.
Gonadotrophin data: Pre-treatment LH/FSH levels were low (<0.7/3) but early stimulation was apparent (DI + 2 h: >50/> 80). Over the period of study the effect of the daily injection remained stimulatory, although this effect became blunted with time (D16, pre-injection: 2/7, +2h 12/12; D22 pre-injection: 4/8, +2h 12/11 Gonadotrophin data: Pre-treatment serum LH/FSH concentrations were low (<0.7/0.5), showed elevation 2h after the first injection (11/45) but thereafter remained profoundly low (<0.7/3). brain and lung metastases. Treatment comprised whole brain radiotherapy and daily ICI 118630 injections. After 4 weeks the lung metastases, as assessed by plain chest Xrays, were worse. Treatment was changed to tamoxifen and a partial response in the pulmonary metastases was achieved and lasted for longer than one year. The primary tumour mass also responded pari passu.
Gondatrophin data: Pre-treatment serum LH/FSH concentrations were elevated (17/24) and rose 2 h after the first injection (47/52). The stimulatory effects of the daily injections were still marked at one week and still just apparent at one month (D28, pre-injection 5/8, + 2 h 9/12). (Harvey et al., 1981) claimed that 12/31 (40%) of postmenopausal women with metastatic cancer benefited from leuprolide treatment but these authors have never definitively published their studies. However, the results are of great interest because hypophysectomy has been known to be effective therapy in postmenopausal women with metastatic breast cancer and its mode of action has never been satisfactorily explained.
In the non-randomised Guy's Hospital series (Hayward et al., 1970) , hypophysectomy proved better than adrenalectomy and Henderson and Canellos (1980) cite anecdotal evidence of a response to hypophysectomy after adrenalectomyboth suggesting the the mode of action was not via the pituitary-adrenal axis.
With the availability of potent long acting LHRH analogues and the discovery that they induce down-regulation of pituitary gonadotrophin receptors, came the opportunity to inhibit the anterior pituitary secretion of gonadotrophins in postmenopausal women with breast cancer without affecting the other anterior pituitary hormones. It is also possible that circulating pharmacological concentrations of a potent LHRH analogue could theoretically have a direct effect on breast cancer cells if they were to possess LHRH receptors. There are some laboratory data which demonstrate LHRH receptors in breast tumours (Lamberts et al., 1982) , and recently Eidine et al. (1985) and Miller et al. (1985) have described LHRH binding sites in human breast carcinoma cells.
In the study reported here, two postmenopausal women showed an objectively measured and durable remission of the metastatic breast cancer (in bones and lungs respectively) following therapy with the potent LHRH analogue ICI 118630. One of these responses was interpreted from the disappearance of 'hot spots' from the technetium methylene diphosphonate bone scan in the lumbar spine -where plain X-rays and CT scanning had demonstrated metastatic disease. This response on bone scanning does not meet UICC criteria because the UICC do not accept bone scan responses. Profound suppression of gonadotrophin secretion from the pituitary was achieved in both patients and no other anterior pituitary hormone, nor cortisol, oestrogens nor androgens were perturbed, as measured by serial blood levels throughout the treatment period. Seven patients failed to respond but several points must be made which may be relevant, if the mechanism of response to ICI 118630 is effected by suppression of circulating gonadotrophin levels. The daily s.c. injection of ICI 118630 proved less successful in down-regulating pituitary gonadotrophin secretion than the depot formulation. This fact together with the finite period allowed for drug administration by the local ethical committee in the early part of the study meant that, in several patients, the pituitary gonadotrophin secretion still had not been suppressed fully by the time the drug was stopped. This last observation may confound the response to subsequent tamoxifen, a manoeuvre that had been deliberately built into the study design for nonresponders to ICI 118630. For example, although two responders to tamoxifen were observed, three patients had not fully suppressed their gonadotrophins with daily s. gonadotrophin) and sex steroid blood levels are not perturbed. Thus these other hormones are probably not involved in the mechanism of drug action. If the response is mediated by the inhibition of pituitary gonadotrophin secretion then the true response rate may be higher than the 2/9 reported here as not all patients achieved full suppression in this study. It may be pertinent to note that full suppression was documented in both responders reported here. The length of time from the menopause, the pre-treatment LH/FSH levels and the ER/PR concentrations in the tumour may be possible predictive factors of a response. An alternative possibility is that the long acting LHRH analogues are directly influencing breast tumour growth. The cross-over data to tamoxifen, amongst those failing ICI 118630, requires further study.
